Publicaciones en colaboración con investigadores/as de NewYork–Presbyterian Hospital (4)

2023

  1. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

2019

  1. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

    Blood, Vol. 133, Núm. 18, pp. 1953-1963

2018

  1. Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations

    Blood, Vol. 132, Núm. 7, pp. e13-e23